We serve Chemical Name:2-(4-chlorophenyl)sulfanyl-5-nitrobenzoate CAS:66949-29-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-(4-chlorophenyl)sulfanyl-5-nitrobenzoate
CAS.NO:66949-29-9
Synonyms:2-(4-chlorophenyl)sulfanyl-5-nitrobenzoate
Molecular Formula:C13H7ClNO4S-
Molecular Weight:308.71700
HS Code:2930909090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:502.4ºC at 760 mmHg
Density:1.56g/cm3
Index of Refraction:1.702
PSA:111.25000
Exact Mass:307.97800
LogP:3.28610
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-(4-chlorophenyl)sulfanyl-5-nitrobenzoate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-(4-chlorophenyl)sulfanyl-5-nitrobenzoate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-(4-chlorophenyl)sulfanyl-5-nitrobenzoate Use and application,2-(4-chlorophenyl)sulfanyl-5-nitrobenzoate technical grade,usp/ep/jp grade.
Related News: Pre-approval Access Programs (also known as expanded access, early access, compassionate use, named patient supply) are regulatory-compliant processes permitting experimental agents in development to be made available upon the request of a physician or a patient for appropriate patients for whom no alternative treatment option exists in their country. 2-(4-chlorophenyl)sulfanyl-5-nitrobenzoate manufacturer In the current trial, a total of 196 patients were randomly chosen to receive either the vaccine or a placebo. 2-(4-chlorophenyl)sulfanyl-5-nitrobenzoate supplier In the current trial, a total of 196 patients were randomly chosen to receive either the vaccine or a placebo. 2-(4-chlorophenyl)sulfanyl-5-nitrobenzoate vendor Professionally produce and submit DMF files, and supplement data at any time during the patent challenge of formulation companies. 2-(4-chlorophenyl)sulfanyl-5-nitrobenzoate factory Pre-approval Access Programs (also known as expanded access, early access, compassionate use, named patient supply) are regulatory-compliant processes permitting experimental agents in development to be made available upon the request of a physician or a patient for appropriate patients for whom no alternative treatment option exists in their country.
